<DOC>
	<DOCNO>NCT02453282</DOCNO>
	<brief_summary>This randomize , open-label , multi-center , global , Phase III study determine efficacy safety MEDI4736 + tremelimumab combination therapy MEDI4736 monotherapy versus platinum-based SoC chemotherapy first-line treatment patient epidermal growth factor receptor ( EGFR ) anaplastic lymphoma kinase ( ALK ) wild-type locally advance metastatic NSCLC</brief_summary>
	<brief_title>Phase III Open Label First Line Therapy Study MEDI 4736 ( Durvalumab ) With Without Tremelimumab Versus SOC Non Small-Cell Lung Cancer ( NSCLC ) .</brief_title>
	<detailed_description>Patients randomize 1:1:1 ratio receive treatment MEDI4736 + tremelimumab combination therapy , MEDI4736 monotherapy , Standard Care ( SoC ) therapy .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For inclusion study , patient fulfill follow criterion : Aged least 18 year Documented evidence Stage IV NSCLC No sensitize EGFR mutation ALK rearrangement No prior chemotherapy systemic therapy recurrent/metastatic NSCLC World Health Organization ( WHO ) Performance Status 0 1 Patients enter study follow exclusion criterion fulfil : 1 . Mixed smallcell lung cancer NSCLC histology , sarcomatoid variant 2 . Brain metastasis spinal cord compression unless asymptomatic , treat stable ( require steroid ) 3 . Prior exposure Immunomodulatory therapy ( IMT ) , include , limited , anticytotoxic Tlymphocyteassociated antigen 4 ( CTLA4 ) , antiprogrammed cell death1 ( PD1 ) , antiprogrammed cell death ligand 1 ( PDL1 ) , anti PDL2 antibody , exclude therapeutic anticancer vaccine 4 . Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease [ eg , colitis Crohn 's disease ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NSCLC , PD-L1 , MEDI4736 , Tremelimumab , PFS , OS</keyword>
</DOC>